Jung Won Shin

Senior Editor of Scrip Intelligence/The Pink Sheet @PharmaScrip @PharmaPinkSheet All views are mine.

[Lisa Takagi @scriplisatakagi]

Japan Awards Global-First Reimbursement To Ishin’s Allostem, Heihe’s Risovalisib
Japan sets reimbursement prices for four new therapies, including two which recently received global-first approvals in the country.
https://t.co/oa5WjNDQvO

[Jung Won Shin @ScripJungWon]

#Prazer CEO talks to Scrip how the #Korean #biotech is advancing its proprietary #TPD platform, designed to target both proteasome and lysosomal degradation pathways to address targets inaccessible to conventional approaches, @PharmaScrip reports.
https://t.co/EIokWJVFan

[Jung Won Shin @ScripJungWon]

#LigaChem secures hefty new financing from South #Korea's National Growth Fund, marking the first domestic #bioventure to benefit from the broad economic initiative, reports @PharmaScrip.
https://t.co/bIKpwCRbgF

[Jung Won Shin @ScripJungWon]

Latest Korean mini-podcast on @PharmaScrip story "Pharma Sales To Top $2 Trillion As The Big Drug Era Beds In."
https://t.co/hzzhPSMP5k

[Jung Won Shin @ScripJungWon]

#Korean #pharma companies are rapidly integrating #AI across drug discovery, manufacturing and patient management, driven by both corporate strategy and aggressive government-backed AI investment programs, reports @PharmaScrip.
https://t.co/isXuK18qrn

[Jung Won Shin @ScripJungWon]

#Insilico #Medicine and #SK #Biopharmaceuticals sign a CNS-focused, AI-powered #drug discovery collaboration worth up to $2.5bn, pairing the former's tech platform with the #Korean company's clinical and commercial capabilities, reports @PharmaScrip.
https://t.co/n7c7A8knJT

[Jung Won Shin @ScripJungWon]

#Korean biopharma companies are advancing and expanding their #obesity drug pipelines, with a focus on next-generation approaches including multi-target agonists, muscle-preserving therapies and oral formulations, reports @PharmaScrip.
https://t.co/mAM9Mz5nLQ

[Lisa Takagi @scriplisatakagi]

ポッドキャスト、久々の更新です🙂
【3分で解説 #世界のファーマ】第29回　米国を悩ませる医薬品不足のいま
https://t.co/rW7hzqzs5q

[Lisa Takagi @scriplisatakagi]

Japan's regulatory authorities escalate action against widespread off-label use of Mounjaro for weight loss amid continued open promotion by clinics of such non-reimbursed administration. https://t.co/Y4GbTFrPIO

[Jung Won Shin @ScripJungWon]

#KHIDI president Soon-Do Cha talks to @PharmaPinkSheet about how the #Korean government agency is transforming into a full-lifecycle #biohealth industry support platform and its policy priorities over the near term.
https://t.co/GQt4qw9Gu6

[Jung Won Shin @ScripJungWon]

Citeline's latest Korean language podcast on @PharmaScrip's interview with #Flagship Pioneering https://t.co/qs7QwEkKbl

[Jung Won Shin @ScripJungWon]

#KHIDI president Soon-Do Cha talks to @PharmaScrip about why #Korea’s significance as a global #pharma partner is rising, what’s driving recent platform #deals, and the government agency’s breadth of support for Korean companies.
https://t.co/n2DHLk5fBA

[Jung Won Shin @ScripJungWon]

#Deal expands #Agios's rare #hematology portfolio in high-need area and marks another major global alliance involving #Oscotec, validating the #Korean industry's rising competitiveness in #innovative drug development,@PharmaScrip reports.
https://t.co/bdq0EdVvdf

[Jung Won Shin @ScripJungWon]

#Lilly secures global rights to #Hanmi’s long-acting GLP-2 analog sonefpeglutide for short bowel syndrome and other indications, in a deal worth up to $1.26bn plus royalties, @PharmaScrip reports.
https://t.co/eaBSehhb89

[Jung Won Shin @ScripJungWon]

A #Bio Korea session says #Korea must develop stronger commercialization expertise, share the financial burden of late-stage trials, and foster closer government, industry collaboration if it is to produce global blockbuster drugs, reports @PharmaScrip.
https://t.co/yyU494cPMi

[Vibha Ravi @scripvibha]

Yesss. We pointed out the strength of Wockhardt’s data for its novel drug and now Zaynich is approved by the US FDA. Comes after India' CDSCO greenlight for the antibiotic #pharma #biotech #marketing https://t.co/leLz5UmERr

[Lisa Takagi @scriplisatakagi]

Not disclosing an overall sales target under its new mid-term plan, Astellas aims to mitigate Xtandi’s patent cliff with growth for existing products and the launch of late-stage candidates, while cutting costs.
https://t.co/v4OLrW6iS9

[Jung Won Shin @ScripJungWon]

South Korea aims for "world’s fastest review period" for medical products under new measures from June, with focus on increased staff, parallel reviews and pre-filing checklists and consultations, reports @PharmaPinkSheet.
https://t.co/ERb42LvSZF

[Lisa Takagi @scriplisatakagi]

Japan Pricing Roundup: $350k For Sumitomo’s iPSC Parkinson’s Therapy
Sumitomo Pharma set to become first company worldwide to commercialize an iPSC therapy following Japanese reimbursement of Amchepry for Parkinson’s disease.
https://t.co/dQArRmjlzI

[Lisa Takagi @scriplisatakagi]

Kissei Urges Tavneos Caution In Japan After 20 Deaths
Reports of deaths, including cases of vanishing bile duct syndrome, in patients in Japan receiving Tavneos make local headlines and prompt new precautionary measures by local licensee Kissei.
https://t.co/QVCeTSqSY0